Screener
Bio-Rad Laboratories BIO Net Income
Discontinued — last reported Q1 '26
Net Income at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:19 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000012208-26-000035
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Other income, net | (24.2) | (37.2) |
| Income (loss) before income taxes | (689.8) | 83.4 |
| (Provision for) benefit from income taxes | 162.7 | (19.4) |
| Net income (loss) | $(527.1) | $64.0 |
| Basic earnings (loss) per share: | ||
| Net income (loss) per basic share | $(19.55) | $2.29 |
| Weighted average common shares - basic | 26,958 | 27,941 |
| Diluted earnings (loss) per share: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bio-Rad Laboratories's net income?
- Bio-Rad Laboratories (BIO) reported net income of -$527.1M in Q1 2026.
- How has Bio-Rad Laboratories's net income changed year-over-year?
- Bio-Rad Laboratories's net income decreased by 923.6% year-over-year, from $64M to -$527.1M.
- What is the long-term trend for Bio-Rad Laboratories's net income?
- Over 4 years (2021 to 2025), Bio-Rad Laboratories's net income has grown at a -35.0% compound annual growth rate (CAGR), from $4.25B to $759.9M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Bio-Rad Laboratories's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude